Last reviewed · How we verify
SB656933
At a glance
| Generic name | SB656933 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis (PHASE2)
- 28 Day Repeat Dose in Cystic Fibrosis Patients (PHASE2)
- Repeat Dose Study in Male Healthy Volunteer Smokers (PHASE1)
- Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone (PHASE1)
- A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects (PHASE1)
- SD Cystic Fibrosis Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB656933 CI brief — competitive landscape report
- SB656933 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI